BioCurex, Inc.(fka BOCX)

[bocxman]

kag: i have a problem with your statement that to you, the drop after the ABT deal would have been predictable because of no revenue.

stocks trade at a discount to FUTURE earnings/revenue. there are many revenue-less stocks, especially biotechs, that are propelled to lofty market caps with simple partnership announcements, clinical trial data, etc. in fact, many of these stocks start to come down to earth AFTER they launch product, since at that point it becomes a boring old EPS meet/beat game.

IMO, the reasons we came back to exactly where we started was:

1) pink sheets...99%+ of liquidity is unable or unwilling to invest in pink sheet stocks, so there goes the vast majority of available bidding capital.

2) overhead supply from years of loyal supporters being underwater

3) overhead supply from the pre-investigation spike two years ago...a lot of bagholders to say the least.